Lymphangioleiomyomatosis

Research Updates (10)Clinical Trials (10)

Browse recruiting and upcoming clinical trials for lymphangioleiomyomatosis.

Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026

About this listHide

ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.

10 trials

Showing 10 trials

Recruiting
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
NCT01799538
Who can join AIWomen aged 18–100 with lymphangioleiomyomatosis (LAM) who have airflow obstruction.
What is being studied AIWhether nebulized albuterol increases lung function more than inhaled (MDI) albuterol.
Study typeTreatment (drug) · Phase 1/2
CountriesUnited States
View trial
Recruiting
The Genotype and Phenotype of Lymphangioleiomyomatosis
NCT06405997
Who can join AIAdults (age ≥18) with chest CT–shown cystic lung disease suspected to be lymphangioleiomyomatosis (sporadic or TSC-associated).
What is being studied AICollects genotype and phenotype information to compare sporadic and TSC-associated LAM.
Study typeObservational
CountriesTaiwan
View trial
Recruiting
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Who can join AIAdults (18+) with lymphangioleiomyomatosis (LAM) who are considering, taking, or who have previously tried mTOR inhibitor therapy.
What is being studied AIRecords long-term safety and lung function (FEV1) in LAM patients taking mTOR inhibitors.
Study typeObservational
CountriesUnited States
View trial
Recruiting
National Lymphangioleiomyomatosis Registry, France
NCT01484236
Who can join AIAdults (18+) with lymphangioleiomyomatosis, including sporadic or Tuberous sclerosis–associated cases.
What is being studied AICollects medical and demographic data to estimate incidence, prevalence, and disease course.
Study typeObservational
CountriesFrance
View trial
Recruiting
Study of the Disease Process of Lymphangioleiomyomatosis
NCT00001465
Who can join AIPeople with lymphangioleiomyomatosis and related lung conditions, including pneumothorax and tuberous sclerosis–associated lung disease.
What is being studied AICollects clinical data, imaging, and genetic and protein analyses to study LAM disease processes.
Study typeObservational
CountriesUnited States
View trial
Enrolling by invitation
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
NCT05727852
Who can join AIAdults (18+) with chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis, other ILDs) and healthy adults.
What is being studied AICompares exhaled volatile organic compounds and arterial stiffness measures between patients and healthy adults.
Study typeObservational
CountriesRussia
View trial
Recruiting
TSC Biosample Repository and Natural History Database
NCT05676099
Who can join AIPeople of any age with tuberous sclerosis complex (TSC) or with sporadic lymphangioleiomyomatosis (LAM).
What is being studied AICollects and stores biosamples and linked clinical data from people with TSC or sporadic LAM.
Study typeRegistry
CountriesCanada, United States
View trial